[ILS-FR-17] Lunch Seminar 17: Ranibizumab: transformational outcomes in patients with DME and RVO
- Apr 04 (Fri)
- 12:15 - 13:15
- Room 2 - Tokyo International Forum 4,5F Hall C
- Novartis Pharma AG
- Retina, Vitreous body
- Chair）Yuichiro Ogura、Chair）José Cunha-Vaz
- It is increasingly clear that, in DME and RVO, early-stage pathology is driven by VEGF. Consequently, physicians should endeavor to initiate early treatment using anti-VEGF agents. Comorbidities in patients with DME and RVO may mandate the use of anti-VEGF treatments with minimal systemic exposure to optimize the benefit-risk ratio. Data from recent clinical trials of ranibizumab demonstrate significant visual and anatomic improvements and minimal systemic exposure with an individualized treatment regimen. With the wealth of available evidence and its well-established safety profile, ranibizumab is a preferred option in the treatment of patients with DME and RVO (both BRVO and CRVO).